In addition, it was found that the use of olaparib and CSF-1R inhibitors in the BRCA-proficient mouse tumor model had no significant therapeutic effect, indicating that tumor immunotherapy was related to BRCA status. This evidence concerns the gene CSF1R and neoplasm.